Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Kates

Showing results (141-150 of 157) with videos related to

Pageof 16
Sort By:
Nature Communications|February 16, 2022
Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancerAlok Kumar Singh, Monali Praharaj, Kara A Lombardo, et al.
BJU International|October 12, 2021
Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registryHamed Ahmadi, Seyedeh Sanam Ladi-Seyedian, Badrinath Konety, et al.
Urologic Oncology|November 26, 2022
Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?Muhannad Alsyouf, Seyedeh-Sanam Ladi-Seyedian, Badrinath Konety, et al.
Nature Communications|March 24, 2026
Retraction Note: Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancerAlok Kumar Singh, Monali Praharaj, Kara A Lombardo, et al.
The Journal of Pathology|November 3, 2021
BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancerKara A Lombardo, Aleksandar Obradovic, Alok Kumar Singh, et al.
Urologic Oncology|June 7, 2021
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCGRyan L Steinberg, Vignesh T Packiam, Lewis J Thomas, et al.
The Journal of Urology|August 27, 2021
Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and SurvivalHiten D Patel, Sunil H Patel, Enrique Blanco-Martinez, et al.
Urology|October 17, 2017
Hospital Charges and Length of Stay Following Radical Cystectomy in the Enhanced Recovery After Surgery EraAlice Semerjian, Niv Milbar, Max Kates, et al.
The Journal of Urology|October 25, 2021
Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study ComparisonsMeera R Chappidi, Heiko Yang, Maxwell V Meng, et al.
The Journal of Urology|December 11, 2019
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder CancerRyan L Steinberg, Lewis J Thomas, Nathan Brooks, et al.
Pageof 16

Showing results (141-150 of 157) with videos related to

Sort By:
Pageof 16
Nature Communications|February 16, 2022
Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancerAlok Kumar Singh, Monali Praharaj, Kara A Lombardo, et al.
BJU International|October 12, 2021
Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registryHamed Ahmadi, Seyedeh Sanam Ladi-Seyedian, Badrinath Konety, et al.
Urologic Oncology|November 26, 2022
Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?Muhannad Alsyouf, Seyedeh-Sanam Ladi-Seyedian, Badrinath Konety, et al.
Nature Communications|March 24, 2026
Retraction Note: Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancerAlok Kumar Singh, Monali Praharaj, Kara A Lombardo, et al.
The Journal of Pathology|November 3, 2021
BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancerKara A Lombardo, Aleksandar Obradovic, Alok Kumar Singh, et al.
Urologic Oncology|June 7, 2021
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCGRyan L Steinberg, Vignesh T Packiam, Lewis J Thomas, et al.
The Journal of Urology|August 27, 2021
Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and SurvivalHiten D Patel, Sunil H Patel, Enrique Blanco-Martinez, et al.
Urology|October 17, 2017
Hospital Charges and Length of Stay Following Radical Cystectomy in the Enhanced Recovery After Surgery EraAlice Semerjian, Niv Milbar, Max Kates, et al.
The Journal of Urology|October 25, 2021
Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study ComparisonsMeera R Chappidi, Heiko Yang, Maxwell V Meng, et al.
The Journal of Urology|December 11, 2019
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder CancerRyan L Steinberg, Lewis J Thomas, Nathan Brooks, et al.
Pageof 16